A panel of experts discussed decentralized web and Web3 technology — and its potential for impacting communities. Photo courtesy of DivInc

Houston innovators dispelled some of the misconceptions about the decentralized web and Web3 technology at a recent Ion panel, highlighting the technology’s ability to bring communities together.

DivInc, a Texas-based accelerator focused on helping BIPOC and female founders on their entrepreneurial journeys, hosted a panel to discuss the benefits of transitioning to DWeb for entrepreneurs, personal success stories of using Web3 technology, and promoted its inaugural DWeb for Social Impact Accelerator.

The panelists included Giorgio Villani, founder of Spindletop Digital; Akeel Bernard, community development manager of Impact Hub Houston; and Ayoola John, co-founder and CEO of Astronaut. The discussion was moderated by Cherise Luter, marketing director of DivInc.

With the application for the DWeb 12-week accelerator program live, announced earlier this year, Luter says the panel was initiated to help explain the links between impact entrepreneurship and DWeb, two areas that people may think are very separate.

“This is our first time hosting a social impact accelerator here in Houston and we’re really excited about it. We added this extra piece of Web3, DWeb – how social entrepreneurs are utilizing this new technology to push forward their vision and bring about their startups,’” Luter says.

Villani, a founder of multiple companies that employ Web3 innovation, defined this technology as a tool of decentralization in which users are responsible for their own data and transactions are kept transparent by being publicly accessible. Villani contrasted this setup to the modern internet, known as Web2, in which users entrust third parties with encrypting their personal data, allowing them to mine and profit from this information.

“Web3 is a flipping of the script a little bit – it’s where we’re focusing primarily on the individual, where the individual is being empowered. Everybody manages their own keys and you don’t have to trust a third party to do anything within the system … you don’t have to cede your power to third party entities – it’s really an empowering thing to do,” Villani explains.

Villani addressed the misunderstanding that the decentralized web is too complicated for the average person to use by highlighting his partnership with multimedia Houston artist J. Omar Ochoa. Ochoa is incorporating Web3 technologies like AI and NFTs into an exhibit, allowing him to interact directly with buyers.

“The misconception is that (Web3) is difficult or too technical and it’s really not. There’s some stuff that takes a little bit of work but once you’ve done that the whole world of Web3 opens up in front of you,” Villani says.

For Villani, Web3 technologies are about the opportunity for connection.

“When you look around you, a lot of people these days are lonely and it’s funny because we have these platforms like Facebooks, Instagrams, WhatsApps, Snapchats and they’re all designed to bring us together but if you really look around you we’re not together,” Villani explains. “For me fundamentally, we have to reimagine how we build social networks, how we connect people.”

Web3 technologies are not all inherently about decentralization of the internet so much as rethinking how to rebuild the web to bring people together based on shared interests, adds John, co-founder of a social impact company that uses Web3 to help brands build online communities.

In contrast to much of the tech world, John also says that NFTs and cryptocurrencies, both of which are considered Web3 tools as they operate on blockchains, are not components of DWeb because they are tied up by monopolies. As the majority of NFTs are sold on one website and Bitcoin continues to dominate the cryptocurrency market, John explains they can not qualify as decentralized.

“I believe I can make an argument that crypto at its core is not about decentralization. What I believe crypto is and the Web3 movement is about reimagination,” John shares.

Bernard, who works directly with social impact entrepreneurs at Impact Hub Houston, says he anticipates founders looking to secure investors for their DWeb related companies will struggle, at first, because they must concisely explain the technology and business model at play. Bernard says he previously coached entrepreneurs on how to explain to investors that investing in social impact companies is not charity but a typical investment that will pay returns. Bernard expects DWeb focused companies will face similar uphill battles of getting investors to understand their concepts.

“I think with DWeb because it’s a newer network it’s going to require social impact entrepreneurs to educate investors and also users on the benefits of DWeb,” Bernard explains. “You’re going to have to be able to explain to them in a clear and consistent way especially to the investors, folks that have the means but don’t understand what DWeb is, how it can be utilized for success.”

Photo courtesy of DivInc

DivInc has announced a new program that will support BIPOC and women founders of social enterprise startups working on Web3 technology. Photo via divinc.org

Texas nonprofit introduces newest accelerator to be hosted in Houston this fall

apply now

A Texas accelerator that's focused on supporting traditionally marginalized entrepreneurs has announced its newest program.

DivInc has introduced DWeb for Social Impact Accelerator, a new program set to support BIPOC and women founders of social enterprise startups developing global solutions with DWeb and Web3 technologies — such as blockchain, crypto-asset, artificial intelligence, machine learning, augmented reality, and more.

The first cohort of the program, which is supported by the Filecoin Foundation for the Decentralized Web, or FFDW, will run from September through November at the Ion. Applications are open now.

"Through the DWeb for Social Impact Accelerator we are marrying activism with the decentralized web in a way that builds these startups and puts them at the forefront of solving society's toughest challenges," says Preston James, CEO at DivInc, in a news release. "We want to see our creative tech economy founders playing a major role in building and benefiting from DWeb and Web3 for the greater good. This partnership with FFDW is a huge leap forward in that pursuit."

The 12-week accelerator will support up to 10 companies, and, at the end of the program, each selected company will receive $10,000 in non-dilutive seed funding. In addition to FFDW, the program is supported by Houston Premier Partners, J.P. Morgan Chase & Co., Verizon, The Ion, and Mercury.

"A core part of FFDW's mission is education about the decentralized web," says Marta Belcher, president and chair of Filecoin Foundation for the Decentralized Web, in the release. "FFDW is absolutely thrilled to bring more diverse voices into the Web3 ecosystem."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.